An investigation on behalf of investors in Curis, Inc. (NASDAQ:CRIS) shares over potential wrongdoing at Curis, Inc. was announced.
San Diego, CA -- (SBWIRE) -- 08/24/2021 -- An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Curis, Inc.
Investors who purchased shares of Curis, Inc. (NASDAQ: CRIS) have certain options and should contact the Shareholders Foundation at firstname.lastname@example.org or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Curis, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Lexington, MA based Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Curis, Inc. reported that its annual Total Revenue rose from $10 million in 2019 to $10.83 million in 2020, and that its Net Loss declined from $32.14 million in 2019 to $29.9 million in 2020.
On June 11, 2021, Curis, Inc. issued a press release "announc[ing] updated data from its ongoing Phase 1/2 open-label, single arm, dose escalation and expansion trial of CA-4948, a novel, small molecule IRAK4 kinase inhibitor, in patients with acute myeloid leukemia (AML) or high-risk myelodysplastic syndromes (MDS) at the European Hematology Association 2021 Virtual Congress (EHA). Specifically, Curis stated that it had "concluded 300mg BID is the optimal dose to take into Phase 2 studies" after the 500 mg and 400 mg versions of the drug showed dose-limited toxicities. Shares of Curis, Inc. (NASDAQ: CRIS) declined from $15.60 per share on June 8, 2021 to as low as $7.11 per share on June 22, 2021.
Those who purchased shares of Curis, Inc. (NASDAQ: CRIS) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, , which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigation, and/or settlements are not filed/reached and/or related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.